We are live on ! Find out more

729 hedge funds and large institutions have $11.8B invested in Sanofi in 2025 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 281 increasing their positions, 259 reducing their positions, and 100 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more call options, than puts

Call options by funds: $87.6M | Put options by funds: $80.3M

8% more repeat investments, than reductions

Existing positions increased: 281 | Existing positions reduced: 259

5% less funds holding

Funds holding: 771729 (-42)

11.1% less ownership

Funds ownership: 21.07%9.97% (-11%)

18% less capital invested

Capital invested by funds: $14.4B → $11.8B (-$2.59B)

31% less first-time investments, than exits

New positions opened: 69 | Existing positions closed: 100

67% less funds holding in top 10

Funds holding in top 10: 124 (-8)

Holders
729
Holders Change
-42
Holders Change %
-5.45%
% of All Funds
9.6%
Holding in Top 10
4
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-66.67%
% of All Funds
0.05%
New
69
Increased
281
Reduced
259
Closed
100
Calls
$87.6M
Puts
$80.3M
Net Calls
+$7.3M
Net Calls Change
+$1.06M

SNY Hedge Fund Activity: Q2 2025 in Review

729 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2025, worth a combined $11.8B — down 18% from $14.4B a quarter earlier.

Sellers outnumbered buyers: 100 funds closed out of SNY and 69 opened new positions — a net loss of 31 holders — while 259 trimmed existing stakes and 281 added.

The largest buyer was Raymond James Financial, adding an estimated $135M. The largest seller was T. Rowe Price Associates, cutting an estimated $282M.

  • 729 institutional investors held Sanofi (SNY) as of Q2 2025, down from 771 in Q1 2025.
  • Funds reported $11.8B of Sanofi stock for Q2 2025, down 18% quarter-over-quarter.
  • 69 funds opened new Sanofi positions in Q2 2025 and 100 closed out, a net change of -31 holders.
  • The largest Sanofi buyer in Q2 2025 was Raymond James Financial, an estimated $135M added.
  • The largest Sanofi seller in Q2 2025 was T. Rowe Price Associates, an estimated $282M sold.

Based on aggregated 13F filings for Q2 2025.